Yahong Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yahong Cheng has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Hong Ding
Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Wuhan University, Wuhan, China
3 shared publications Lu Zhang
Key Laboratory of Combinatorial Biosynthesis and Drug Discovery
2 shared publicationsQianying Zhang
Key Laboratory of Combinatorial Biosynthesis and Drug Discovery
2 shared publicationsXiaofang Chen
Key Laboratory of Combinatorial Biosynthesis and Drug Discovery
2 shared publicationsYonggang Liu
Key Laboratory of Combinatorial Biosynthesis and Drug Discovery
2 shared publicationsBowen Zhang
Wuhan Polytechnic University
1 shared publication
Latest Publications
- 8 December 2025
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 29 (6) , 764-780
Luteolin rescues myelin integrity and cognitive-motor function via Nrf2 pathway activation: a natural candidate vs. dimethyl fumarate in cuprizone-induced multiple sclerosis
Objective: Targeting the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway represents a promising therapeutic strategy for multiple sclerosis (MS). However, approved drugs like dimethyl fumarate (DMF) often induce severe side effects. This study investigated the natural flavonoid luteolin (LUT) as a potential dietary supplement alternative to DMF in a cuprizone (CPZ)-induced demyelination mouse model of MS.Methods: Mice were randomly assigned to five groups: control, CPZ model, CPZ+DMF (15 mg/kg), CPZ+LUT (25 mg/kg), and CPZ+LUT (50 mg/kg). Motor coordination and spatial memory were assessed via rotarod and Morris water maze tests. Myelin integrity was evaluated by Luxol fast blue staining and myelin basic protein (MBP) immunofluorescence/Western blot. Oxidative stress was measured by assessing superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px) activities and malondialdehyde (MDA) levels. Nrf2 pathway activation was analyzed by nuclear translocation of Nrf2 and expression of downstream proteins (HO-1, NQO1) via Western blot. Molecular docking simulated interactions between compounds and the Keap1 protein.Results: LUT treatment significantly restored motor coordination and spatial memory, with efficacy comparable to DMF. It promoted MBP expression, attenuated oxidative damage by modulating SOD, CAT, GSH-Px, and MDA levels, and preserved myelin integrity. Furthermore, LUT markedly facilitated Nrf2 nuclear translocation and upregulated HO-1 and NQO1 expression. Molecular docking indicated that LUT possessed stronger binding affinity to the target protein Keap1 and a lower potential for off-target toxicity compared to the primary active metabolite of DMF.Conclusion: Luteolin exerts significant neuroprotective effects, primarily via Nrf2 pathway activation, with efficacy parallel to DMF but a superior safety profile. These findings identify LUT as a promising natural compound, bridging functional foods and MS therapy, and provide a foundation for developing LUT-enriched dietary regimens as an adjunct treatment strategy for MS.
- 8 December 2025
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 29 (6) , 764-780
Luteolin rescues myelin integrity and cognitive-motor function via Nrf2 pathway activation: a natural candidate vs. dimethyl fumarate in cuprizone-induced multiple sclerosis
Objective: Targeting the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway represents a promising therapeutic strategy for multiple sclerosis (MS). However, approved drugs like dimethyl fumarate (DMF) often induce severe side effects. This study investigated the natural flavonoid luteolin (LUT) as a potential dietary supplement alternative to DMF in a cuprizone (CPZ)-induced demyelination mouse model of MS.Methods: Mice were randomly assigned to five groups: control, CPZ model, CPZ+DMF (15 mg/kg), CPZ+LUT (25 mg/kg), and CPZ+LUT (50 mg/kg). Motor coordination and spatial memory were assessed via rotarod and Morris water maze tests. Myelin integrity was evaluated by Luxol fast blue staining and myelin basic protein (MBP) immunofluorescence/Western blot. Oxidative stress was measured by assessing superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px) activities and malondialdehyde (MDA) levels. Nrf2 pathway activation was analyzed by nuclear translocation of Nrf2 and expression of downstream proteins (HO-1, NQO1) via Western blot. Molecular docking simulated interactions between compounds and the Keap1 protein.Results: LUT treatment significantly restored motor coordination and spatial memory, with efficacy comparable to DMF. It promoted MBP expression, attenuated oxidative damage by modulating SOD, CAT, GSH-Px, and MDA levels, and preserved myelin integrity. Furthermore, LUT markedly facilitated Nrf2 nuclear translocation and upregulated HO-1 and NQO1 expression. Molecular docking indicated that LUT possessed stronger binding affinity to the target protein Keap1 and a lower potential for off-target toxicity compared to the primary active metabolite of DMF.Conclusion: Luteolin exerts significant neuroprotective effects, primarily via Nrf2 pathway activation, with efficacy parallel to DMF but a superior safety profile. These findings identify LUT as a promising natural compound, bridging functional foods and MS therapy, and provide a foundation for developing LUT-enriched dietary regimens as an adjunct treatment strategy for MS.
- 9 January 2024
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (12) , 3962-3981
Nicotinamide mononucleotide alleviates seizures via modulating SIRT1‐PGC‐1α mediated mitochondrial fusion and fission
Both human and animal experiments have demonstrated that energy metabolism dysfunction in neurons after seizures is associated with an imbalance in mitochondrial fusion/fission dynamics. Effective neuronal mitochondrial dynamics regulation strategies remain elusive. Nicotinamide mononucleotide (NMN) can ameliorate mitochondrial functional and oxidative stress in age‐related diseases. But whether NMN improves mitochondrial energy metabolism to exert anti‐epileptic effects is unclear. This study aims to clarify if NMN can protect neurons from pentylenetetrazole (PTZ) or Mg2+‐free‐induced mitochondrial disorder and apoptosis via animal and cell models. We established a continuous 30‐day PTZ (37 mg/kg) intraperitoneal injection‐induced epileptic mouse model and a cell model induced by Mg2+‐free solution incubation to explore the neuroprotective effects of NMN. We found that NMN treatment significantly reduced the seizure intensity of PTZ‐induced epileptic mice, improved their learning and memory ability, and enhanced their motor activity and exploration desire. At the same time, in vitro and in vivo experiments showed that NMN can inhibit neuronal apoptosis and improve the mitochondrial energy metabolism function of neurons. In addition, NMN down‐regulated the expression of mitochondrial fission proteins (Drp1 and Fis1) and promoted the expression of mitochondrial fusion proteins (Mfn1 and Mfn2) by activating the SIRT1‐PGC‐1α pathway, thereby inhibiting PTZ or Mg2+‐free extracellular solution‐induced mitochondrial dysfunction, cell apoptosis, and oxidative stress. However, combined intervention of SIRT1 inhibitor, Selisistat, and PGC‐1α inhibitor, SR‐18292, eliminated the regulatory effect of NMN pre‐treatment on mitochondrial fusion and fission proteins and apoptosis‐related proteins. Therefore, NMN intervention may be a new potential treatment for cognitive impairment and behavioral disorders induced by epilepsy, and targeting the SIRT1‐PGC‐1α pathway may be a promising therapeutic strategy for seizures. image
- 9 January 2024
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (12) , 3962-3981
Nicotinamide mononucleotide alleviates seizures via modulating SIRT1‐PGC‐1α mediated mitochondrial fusion and fission
Both human and animal experiments have demonstrated that energy metabolism dysfunction in neurons after seizures is associated with an imbalance in mitochondrial fusion/fission dynamics. Effective neuronal mitochondrial dynamics regulation strategies remain elusive. Nicotinamide mononucleotide (NMN) can ameliorate mitochondrial functional and oxidative stress in age‐related diseases. But whether NMN improves mitochondrial energy metabolism to exert anti‐epileptic effects is unclear. This study aims to clarify if NMN can protect neurons from pentylenetetrazole (PTZ) or Mg2+‐free‐induced mitochondrial disorder and apoptosis via animal and cell models. We established a continuous 30‐day PTZ (37 mg/kg) intraperitoneal injection‐induced epileptic mouse model and a cell model induced by Mg2+‐free solution incubation to explore the neuroprotective effects of NMN. We found that NMN treatment significantly reduced the seizure intensity of PTZ‐induced epileptic mice, improved their learning and memory ability, and enhanced their motor activity and exploration desire. At the same time, in vitro and in vivo experiments showed that NMN can inhibit neuronal apoptosis and improve the mitochondrial energy metabolism function of neurons. In addition, NMN down‐regulated the expression of mitochondrial fission proteins (Drp1 and Fis1) and promoted the expression of mitochondrial fusion proteins (Mfn1 and Mfn2) by activating the SIRT1‐PGC‐1α pathway, thereby inhibiting PTZ or Mg2+‐free extracellular solution‐induced mitochondrial dysfunction, cell apoptosis, and oxidative stress. However, combined intervention of SIRT1 inhibitor, Selisistat, and PGC‐1α inhibitor, SR‐18292, eliminated the regulatory effect of NMN pre‐treatment on mitochondrial fusion and fission proteins and apoptosis‐related proteins. Therefore, NMN intervention may be a new potential treatment for cognitive impairment and behavioral disorders induced by epilepsy, and targeting the SIRT1‐PGC‐1α pathway may be a promising therapeutic strategy for seizures. image
- 28 April 2022
- Published by Elsevier in European Journal of Pharmacology
- Vol. 925, 174974
Propionate ameliorates diabetes-induced neurological dysfunction through regulating the PI3K/Akt/eNOS signaling pathway
- 28 April 2022
- Published by Elsevier in European Journal of Pharmacology
- Vol. 925, 174974
Propionate ameliorates diabetes-induced neurological dysfunction through regulating the PI3K/Akt/eNOS signaling pathway
- 1 November 2019
- Published by Elsevier in Biochemical Pharmacology
- Vol. 169, 113607
Propionate relieves pentylenetetrazol-induced seizures, consequent mitochondrial disruption, neuron necrosis and neurological deficits in mice
- 1 November 2019
- Published by Elsevier in Biochemical Pharmacology
- Vol. 169, 113607
Propionate relieves pentylenetetrazol-induced seizures, consequent mitochondrial disruption, neuron necrosis and neurological deficits in mice
- Open Access
- 6 July 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (43) , 24470-24476
Apigenin ameliorates vascular injury in rats with high fructose-induced metabolic disturbance by inhibiting PI3K/AKT/GLUT1
(A) Chemical structure of apigenin. (B) Graph illuminating the experimental design for the time course of fructose and apigenin administration, and the timelines for the histological studies, biochemical analysis and western blot analysis.
- 6 July 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (43) , 24470-24476
Open AccessApigenin ameliorates vascular injury in rats with high fructose-induced metabolic disturbance by inhibiting PI3K/AKT/GLUT1
(A) Chemical structure of apigenin. (B) Graph illuminating the experimental design for the time course of fructose and apigenin administration, and the timelines for the histological studies, biochemical analysis and western blot analysis.
- Open Access
- 23 January 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (8) , 4084-4092
α-Lipoic acid alleviates pentetrazol-induced neurological deficits and behavioral dysfunction in rats with seizures via an Nrf2 pathway
Epilepsy (EP) is a type of chronic brain disease characterized by transient central nervous system malfunction which is the result of neuron paradoxical discharge in the brain. In a recent study, we evaluated the neuroprotective effect of α-lipoic acid on pentetrazol-induced rats. Epileptic rats were induced by intraperitoneal injection of pentetrazol (35 mg kg−1), and were intragastrically administered with α-lipoic acid for a month. The treatment with α-lipoic acid significantly reduced the total frequency of epileptic seizures and improved the behavior impairment and cognitive disorder caused by pentetrazol toxicity. With the administration of α-lipoic acid, not only did the apoptosis rate of nerve cells decrease, but also the formation of nitric oxide and malondialdehyde was inhibited. We also recorded evidence suggesting the treatment of α-lipoic acid could enhance the activity of antioxidant enzymes. Furthermore, in the hippocampus area of the brain, α-lipoic acid treatment promoted the translocation of Nrf2 in the nuclear fraction and increased the expression of HO-1 and NQO1. Our data indicated that α-lipoic acid may be a potential candidate for lessening the number of epileptic attacks, improving the behavior and cognitive disorder and cutting down the apoptosis rate of nerve cells in a pentetrazol-induced rat model through activating the Nrf2 signaling pathway.
- 23 January 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (8) , 4084-4092
Open Accessα-Lipoic acid alleviates pentetrazol-induced neurological deficits and behavioral dysfunction in rats with seizures via an Nrf2 pathway
Epilepsy (EP) is a type of chronic brain disease characterized by transient central nervous system malfunction which is the result of neuron paradoxical discharge in the brain. In a recent study, we evaluated the neuroprotective effect of α-lipoic acid on pentetrazol-induced rats. Epileptic rats were induced by intraperitoneal injection of pentetrazol (35 mg kg−1), and were intragastrically administered with α-lipoic acid for a month. The treatment with α-lipoic acid significantly reduced the total frequency of epileptic seizures and improved the behavior impairment and cognitive disorder caused by pentetrazol toxicity. With the administration of α-lipoic acid, not only did the apoptosis rate of nerve cells decrease, but also the formation of nitric oxide and malondialdehyde was inhibited. We also recorded evidence suggesting the treatment of α-lipoic acid could enhance the activity of antioxidant enzymes. Furthermore, in the hippocampus area of the brain, α-lipoic acid treatment promoted the translocation of Nrf2 in the nuclear fraction and increased the expression of HO-1 and NQO1. Our data indicated that α-lipoic acid may be a potential candidate for lessening the number of epileptic attacks, improving the behavior and cognitive disorder and cutting down the apoptosis rate of nerve cells in a pentetrazol-induced rat model through activating the Nrf2 signaling pathway.